Avalo Therapeutics, Inc.

NASDAQ:AVTX

Biotechnology

Healthcare
$6.70 -2.18%

-$0.34 today

Market cap
$387.41M
Beta
0.82
P/E (TTM)
-3.6
EPS (TTM)
-$4.21
52W Low $4.50High $24.27

Volume 1.58M

Average 1.61M

AVTX Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Avalo Therapeutics, Inc.NASDAQ: AVTX

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 20.11M shares rose 91.2% year over year, behind the +130.2% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 8.6% from the prior quarter. Over 3 fiscal years it compounded at +599.3% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +91.2% toward the trailing-twelve-month pace of +130.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
20.11M+8.6% QoQ
Last fiscal yearDec 2025
13.4M+64.9% YoY
LTMMar 2026
15.86M+130.2% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+91.2%——
1 year+64.9%——
3-year CAGR+599.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
13.4M USD
Year-over-year change
+64.9%
4-year CAGR
+338.7%

Weighted Avg Shares vs competitors

How AVTX compares with its peers on the latest reported figures

  • AVTX's LTM Mar 2026 weighted avg shares of 15.86M shares is the 9th highest of the 10 companies compared; the peer median is 68.77M shares.
  • Its year-over-year change of +130.2% is the 2nd highest of 10, against a peer median of +14.6%.
  • Over three fiscal years its annual growth of +599.3% compares with a peer median of +40.1%.
AVTX Competitors Peer median
Weighted Avg Shares for AVTX and competitors
Company Period LTM YoY 3-year CAGR
SYRESpyre Therapeutics, Inc.LTM Sep 2026146.1M +155.9%+166.8%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026124.17M +37.8%+23.4%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 202685.54M +48.0%+78.9%
XNCRXencor, Inc.LTM Jun 202674.94M +5.1%+7.6%
IFRXInflaRx N.V.LTM Mar 202668.77M +14.6%+15.0%
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY202436.24M +0.0%—
ANABAnaptysBio, Inc.LTM Mar 202628.59M -2.5%-0.4%
IMUXImmunic, Inc.LTM Mar 202619.58M +98.7%+69.8%
AVTXAvalo Therapeutics, Inc.LTM Mar 202615.86M +130.2%+599.3%
QTTBQ32 Bio Inc.LTM Mar 202612.77M +5.5%+56.8%
ODTXOdyssey Therapeutics, Inc.—— ——
Peer median (excluding AVTX) 68.77M+14.6%+40.1%

Competitors are the stored peer set for AVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5.4M18.05M1.92M441K59K
Cost of Revenue1.49M3.43M1.28M(366K)0
Gross Profit3.91M14.62M640K807K59K
Gross Margin72.4%81.0%33.3%183.0%100.0%
Research & Development59.84M31.31M13.78M52.08M50.08M
Selling, General & Admin24.66M20.71M10.3M17.24M22.9M
Operating Expenses86.04M52.06M27.99M69.32M72.98M
Depreciation & Amortization1.66M166K158K169K344K
EBITDA(80.5M)(37.29M)(23.29M)(34.85M)(77.75M)
EBITDA Margin-1491.2%-206.6%-1210.3%-7901.6%-131779.7%
Operating Income(82.13M)(37.44M)(27.35M)(68.51M)(72.93M)
Operating Margin-1521.6%-207.4%-1421.6%-15535.6%-123601.7%
Interest Income0003.32M4.35M
Interest Expense2.39M4.17M3.42M00
Other Income / Expenses(2.41M)(4.19M)(4.18M)33.5M(5.17M)
Income Before Tax(84.55M)(41.63M)(31.53M)(35.02M)(78.09M)
Pre-Tax Margin-1566.2%-230.6%-1638.8%-7939.9%-132362.7%
Income Tax Expense(196K)28K14K114K165K
Net Income(84.38M)(41.66M)(31.54M)(35.13M)(78.26M)
Net Margin-1563.1%-230.8%-1639.5%-7965.8%-132642.4%
EPS (Basic)(2,330.66)(1,062.65)(113.58)(4.32)(5.84)
EPS (Diluted)(2,330.66)(1,062.65)(113.58)(3.26)(5.84)
Weighted Avg Shares36.19K39.2K277.73K8.13M13.4M
Weighted Avg Shares (Diluted)36.19K39.2K277.73K10.78M13.4M

Avalo Therapeutics, Inc.

NASDAQ:AVTX

Intrinsic Alpha fair value

Locked

Current Price

$6.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.